ReviewMedical oncology (Northwood, London, England)2015
Review of microRNA in osteosarcoma and chondrosarcoma.
Review in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Carbon-ion beam irradiation combined with miR-17-5p/miR-17-3p inhibitors effectively kill osteosarcoma cells.American journal of cancer research · 2026Article
- Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.Cancers · 2025Review
- The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors.International journal of molecular sciences · 2025Review
- MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma.International journal of molecular sciences · 2024Review
- Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.Cell cycle (Georgetown, Tex.) · 2022Review
- Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p.Cancer cell international · 2022Article
- Long noncoding RNA ADIRF antisense RNA 1 upregulates insulin receptor substrate 1 to decrease the aggressiveness of osteosarcoma by sponging microRNA-761.Bioengineered · 2022Article
- Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages.Lipids in health and disease · 2022Review
- The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets.Frontiers in cell and developmental biology · 2022Review
- Tumor Suppressive Role of miR-342-5p in Human Chondrosarcoma Cells and 3D Organoids.International journal of molecular sciences · 2021Article
- Article
- Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression.Cell death & disease · 2020Article
- LncRNA OR3A4 Regulated the Growth of Osteosarcoma Cells by Modulating the miR-1207-5p/G6PD Signaling.OncoTargets and therapy · 2020Article
- miR‑185 regulates the growth of osteosarcoma cells via targeting Hexokinase 2.Molecular medicine reports · 2019Article
- BMP-2 and miR-29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells.Oncology letters · 2019Article
- MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53.Oncology letters · 2019Article
- microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targetingAmerican journal of cancer research · 2019Article
- LncRNA-SRA1 Suppresses Osteosarcoma Cell Proliferation While Promoting Cell Apoptosis.Technology in cancer research & treatment · 2019Article
- miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.Scientific reports · 2018Article
- MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small noncoding RNAs, which play a complex role in posttranscriptional gene expression and can theoretically be used as a diagnostic or prognostic tool, or therapeutic target for neoplasia. Despite advances in the diagnosis and treatment of skeletal sarcomas, including osteosarcoma and chondrosarcoma, much remains unknown regarding their underpinning molecular mechanisms. Given the recent increasing knowledge base of miRNA roles in neoplasia, both as oncogenes and tumor suppressor genes, this review will focus on the available literature regarding the expression profiles and potential roles of miRNA in skeletal sarcomas. Although this is an emerging field, miRNA profiling may be of use in clarifying competing diagnoses of skeletal sarcomas and possibly indicate patient risk of resistance to traditional chemotherapeutic agents. While detecting and targeting miRNAs is currently limited to experimental investigations, miRNA may be utilized for future clinical management of skeletal sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.